Tissue peptides
TB-500
- 10 mg
Custom strengths on request
Not FDA-approved. Not on FDA's 503A category lists (May 14, 2026). Source, May 14, 2026
At a glance
These dosages are a helpful guide, not a prescription. Every clinician is expected to do their own due diligence before prescribing.
No established human dose
No human or animal efficacy study of TB-500 (Ac-LKKTETQ) itself was identified. Trade press reports that FDA acknowledged 'there are no studies on TB500 itself'. Published work on the fragment is analytical, rat metabolism and in-vitro. Human trials exist only for full-length thymosin beta-4: an IV phase 1 study in healthy volunteers, ophthalmic RGN-259 dry-eye phase 2 trials (mixed efficacy, no safety issues reported), and topical dermal phase 2 trials in stasis and pressure ulcers. These data do not establish TB-500 dosing, safety or efficacy. Related full-length work not used for dosing includes a venous-ulcer design report and a recombinant human Tbeta4 STEMI study.
Get a quote
Custom strengths on request. Prices are quoted per clinic.